DANA DALBAK: Open Payments
NPI 1790721298 · NORMAL, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,222 in 102 payments from 23 companies in 2025. Trend: 2023 $2,419 · 2024 $1,666 · 2025 $2,222
Food & beverage: $2,093Education: $129
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $316 |
| GENZYME CORPORATION | 11 | $236 |
| CSL Behring | 15 | $214 |
| AstraZeneca Pharmaceuticals LP | 10 | $193 |
| Insmed, Inc. | 7 | $149 |
| GlaxoSmithKline, LLC. | 8 | $149 |
| Novartis Pharmaceuticals Corporation | 6 | $138 |
| Amgen Inc. | 6 | $130 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $109 |
| Genentech USA, Inc. | 4 | $103 |
Products named: DUPIXENT, Arikayce, CUVITRU, NEFFY, Xolair, TEZSPIRE, EOHILIA, AIRSUPRA.
Industry payments across IL — which companies pay providers there.
